BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld Asia
Home
» Taiwan, China biopharmas to develop HCV treatment in 1st cross-straits deal
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Taiwan, China biopharmas to develop HCV treatment in 1st cross-straits deal
Nov. 16, 2016
By
Pearl Liu
No Comments
SHANGHAI – Leaving politics aside, a Taiwanese company and a China counterpart plan to set up a $102 million joint venture to develop a dual drug, oral direct-acting antiviral treatment for chronic hepatitis C virus (HCV).
BioWorld Asia